CA3050700C - Use of pridopidine for the treatment of fragile x syndrome - Google Patents

Use of pridopidine for the treatment of fragile x syndrome Download PDF

Info

Publication number
CA3050700C
CA3050700C CA3050700A CA3050700A CA3050700C CA 3050700 C CA3050700 C CA 3050700C CA 3050700 A CA3050700 A CA 3050700A CA 3050700 A CA3050700 A CA 3050700A CA 3050700 C CA3050700 C CA 3050700C
Authority
CA
Canada
Prior art keywords
pridopidine
subject
fxs
fragile
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3050700A
Other languages
English (en)
French (fr)
Other versions
CA3050700A1 (en
Inventor
Michael Hayden
Mahmoud Abdulhossein Pouladi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prilenia Neurotherapeutics Ltd
Agency for Science Technology and Research Singapore
National University of Singapore
Original Assignee
Prilenia Neurotherapeutics Ltd
Agency for Science Technology and Research Singapore
National University of Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd, Agency for Science Technology and Research Singapore, National University of Singapore filed Critical Prilenia Neurotherapeutics Ltd
Publication of CA3050700A1 publication Critical patent/CA3050700A1/en
Application granted granted Critical
Publication of CA3050700C publication Critical patent/CA3050700C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3050700A 2017-01-20 2018-01-18 Use of pridopidine for the treatment of fragile x syndrome Active CA3050700C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762448595P 2017-01-20 2017-01-20
US62/448,595 2017-01-20
PCT/US2018/014169 WO2018136600A1 (en) 2017-01-20 2018-01-18 Use of pridopidine for the treatment of fragile x syndrome

Publications (2)

Publication Number Publication Date
CA3050700A1 CA3050700A1 (en) 2018-07-26
CA3050700C true CA3050700C (en) 2023-10-03

Family

ID=62908348

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3050700A Active CA3050700C (en) 2017-01-20 2018-01-18 Use of pridopidine for the treatment of fragile x syndrome

Country Status (13)

Country Link
US (2) US11234973B2 (https=)
EP (1) EP3570940B1 (https=)
JP (1) JP7114604B2 (https=)
CN (1) CN110505902B (https=)
AU (1) AU2018210145B2 (https=)
BR (1) BR112019015000A2 (https=)
CA (1) CA3050700C (https=)
DK (1) DK3570940T3 (https=)
ES (1) ES2972205T3 (https=)
HU (1) HUE068300T2 (https=)
IL (1) IL268125B2 (https=)
PL (1) PL3570940T3 (https=)
WO (1) WO2018136600A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG188298A1 (en) 2010-09-03 2013-04-30 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
WO2018039475A1 (en) 2016-08-24 2018-03-01 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating dystonias
ES3025836T3 (en) 2016-08-24 2025-06-09 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating functional decline
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
AU2018329628B2 (en) 2017-09-08 2021-04-22 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
EP3920924A4 (en) 2019-02-04 2022-11-16 Prilenia Neurotherapeutics Ltd. LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES
KR102528677B1 (ko) * 2020-01-08 2023-05-04 주식회사 뉴로벤티 리수리드 화합물을 유효성분으로 포함하는 취약 x 증후군 또는 관련 발달 장애 치료용 조성물
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6472736A (en) 1987-09-14 1989-03-17 Toshiba Corp Mri apparatus
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
CN101068782A (zh) 2004-10-13 2007-11-07 神经研究瑞典公司 合成4－(3－磺酰基苯基)－哌啶类的方法
CA2584831C (en) 2004-10-13 2013-09-17 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
EP1961742A1 (en) 2007-02-22 2008-08-27 Novartis AG compounds of formula (I) as serine protease inhibitors
SI2146961T1 (sl) 2007-04-12 2014-08-29 IVAX International GmbH N-oksidni in/ali di-N-oksidni derivati stabilizatorjev/modulatorjev dopaminskega receptorja, ki izkazujejo izboljšane profile kardiovaskularnih stranskih učinkov
TW200848063A (en) * 2007-04-23 2008-12-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
US20100197712A1 (en) 2007-06-18 2010-08-05 Arvid Carlsson Use of dopamine stabilizers
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
CN103080343A (zh) 2010-07-02 2013-05-01 Skf公司 机械部件和用于表面硬化的方法
SG188298A1 (en) 2010-09-03 2013-04-30 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
AU2012209466C1 (en) 2011-01-27 2016-06-23 Neuren Pharmaceuticals Limited Treatment of Autism Spectrum Disorders using Glycyl-L-2-Methylprolyl-L-Glutamic Acid
CN103958469B (zh) 2011-09-07 2016-04-20 梯瓦制药国际有限责任公司 一种新的普利多匹定盐酸盐多晶型形态
MX347209B (es) 2011-12-08 2017-04-19 Teva Pharmaceuticals Int Gmbh La sal de bromhidrato de pridopidina.
HK1206297A1 (en) 2012-04-04 2016-01-08 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
HK1211525A1 (en) 2012-09-27 2016-05-27 Teva Pharmaceutical Industries Ltd. Laquinimod and pridopidine for treating neurodegenerative disorders
EP2900226A4 (en) * 2012-09-27 2016-03-30 Teva Pharma COMBINATION OF RASAGILIN AND PRIDOPIDIN FOR TREATING NEURODEGENERATIVE DISORDERS, ESPECIALLY HUNTINGTON'S DISEASE
PE20160195A1 (es) 2013-06-21 2016-05-14 Teva Pharmaceuticals Int Gmbh Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
PE20161220A1 (es) 2014-01-22 2016-11-23 Teva Pharmaceuticals Int Gmbh Formulaciones de pridopidina de liberacion modificada
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
EP3236964A4 (en) 2014-12-22 2018-09-19 Teva Pharmaceuticals International GmbH L-tartrate salt of pridopidine
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
EP4282479A3 (en) 2015-02-25 2024-02-21 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
CA2993183A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
AU2017326436A1 (en) 2016-09-15 2019-04-11 Prilenia Neurotherapeutics Ltd Use of pridopidine for the treatment of anxiety and depression
JP7436524B2 (ja) 2019-06-12 2024-02-21 プリレニア ニューロセラピューティクス リミテッド ハンチントン病及びその症状を治療するためのプリドピジン及びその類似体を含む組成物

Also Published As

Publication number Publication date
US11234973B2 (en) 2022-02-01
US20220202798A1 (en) 2022-06-30
AU2018210145A1 (en) 2019-08-29
CN110505902A (zh) 2019-11-26
DK3570940T3 (da) 2024-02-19
IL268125A (en) 2019-09-26
HUE068300T2 (hu) 2024-12-28
AU2018210145B2 (en) 2023-06-29
EP3570940A4 (en) 2020-10-28
BR112019015000A2 (pt) 2020-04-07
JP7114604B2 (ja) 2022-08-08
CN110505902B (zh) 2022-11-11
US12551474B2 (en) 2026-02-17
CA3050700A1 (en) 2018-07-26
IL268125B (en) 2022-12-01
ES2972205T3 (es) 2024-06-11
IL268125B2 (en) 2023-04-01
WO2018136600A1 (en) 2018-07-26
JP2020514313A (ja) 2020-05-21
PL3570940T3 (pl) 2024-06-17
US20190336488A1 (en) 2019-11-07
EP3570940A1 (en) 2019-11-27
EP3570940B1 (en) 2023-12-13

Similar Documents

Publication Publication Date Title
US12551474B2 (en) Use of pridopidine for the treatment of fragile X syndrome
US11406625B2 (en) Method of treating amyotrophic lateral sclerosis with pridopidine
AU2021219072B2 (en) Combination therapy for treating amyotrophic lateral using pridopidine and another active agent
Class et al. Patent application title: USE OF PRIDOPIDINE FOR THE TREATMENT OF FRAGILE X SYNDROME Inventors: Michael Hayden (Herzliya, IL) Mahmoud Abdulhossein Pouladi (Singapore, SG) Assignees: PRILENIA NEUROTHERAPEUTICS LTD. NATIONAL UNIVERSITY OF SINGAPORE Agency For Science, Technology and Research
HK40016661A (en) Pridopidine for use in the treatment of fragile x syndrome
HK40016661B (en) Pridopidine for use in the treatment of fragile x syndrome
RU2374245C1 (ru) Лиганд с широким спектром одновременной рецепторной активности, фармацевтическая композиция, способ ее получения и лекарственное средство
HK40025981B (en) Method of treating amyotrophic lateral sclerosis with pridopidine
HK40025981A (en) Method of treating amyotrophic lateral sclerosis with pridopidine
BR122025001464A2 (pt) Uso de pridopidina e, opcionalmente, de um segundo composto para o tratamento de esclerose lateral amiotrófica (ela) e composição farmacêutica

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220425

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241127

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241127

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241127

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251125

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251125